The Crystal Clear Way to Longevity.
Longevity only works if patients stay on therapy. Our focus is on overlooked longevity actives—proven to extend life, but historically limited by poor formulation. Until now.
APPROVED DRUG SUBSTANCES
UP TO 30+ LONGEVITY INDICATIONS
Drug Focus.
We don’t chase new molecules. We build TRUE LONGEVITY by turning proven drugs into patient-friendly, affordable prescription medicines. ORACTIVE creates science- and data-driven longevity products addressing real medical needs, leveraging existing and approved drug substances.
Longevity Indications.
ORACTIVE is building a scalable longevity pipeline, complemented by therapy-supporting supplements. With our ORASMART® platform technology, we scale from an initial focus on two indications to more than 30 longevity therapies across metabolic diseases, chronic care, and beyond.
Our Team
Dr. Timo Schmidt
CEO / FOUNDER
> 25 years of experience in international pharmaceutical companies and consulting. Industrial pharmacist (GER) and PhD (CH); IEMBA at IE Business School Madrid (ES). Unique interdisciplinary knowledge across the pharma value stream: R&D, clinical trials, licensing, QA.
Dr. Thomas Kerscher
MEMBER BOARD OF DIRECTORS
PhD in Pharmacy. CEO Europe at Aspen Pharma until 2023. Senior positions at Procter & Gamble, Novartis, Takeda Pharma.
Georg Tölkhaus
CFO
Master Degree in Economics, Swiss Certified Public Accountant, CFA Charterholder. 20 years of experience in strategic controlling, audit, M&A, and private equity.
Dr. habil. Grzegorz Garbacz
ADVISORY BOARD
PhD in Pharmaceutical Sciences. Inventor of recognized models for the mechanical and physical parameters of the human gastro-intestinal tract. Know-How of simulating GI transit conditions, bio-predictive dissolution testing of oral drugs and development of analytical methods.
Prof. Dr. Werner Weitschies
ADVISORY BOARD
PhD in Pharmaceutical Sciences, Head Institute of Pharmacy at University of Greifswald. Renowned expert for investigation of behavior of dosage forms in human gastrointestinal tract. Author or co-author of more than 250 scientific articles and 31 patents.
Dr. Peter Huber
ADVISORY BOARD
PhD in Natural Sciences (ETH), EMBA (University of St. Gallen). Distinguished career in international pharma and industry associations. Very well-connected with authorities and exponents of (inter)national healthcare and industrial policy.
Dr. Detlev Haack
ADVISORY BOARD
PhD Dr. rer. nat. in Pharmaceutical Technology. > 20 years of experience in pharmaceutical R&D, production, and business development. Outstanding expertise in effervescent technologies. Troubleshooting formulation challenges.
Prof. Dr. Michael Rossbach
ADVISORY BOARD
PhD in Biochemistry, professorship in immunology (Univ. Witten/Herdecke, Harvard, TUM1 Asia). Distinguished academic career. (Co-)Founder of several successful start-up companies.
Annika Schroer
BD & LICENSING
Industrial pharmacist (GER), postgraduate Master Degree in Drug Regulatory Affairs (GER). > 20 years of experience in international pharmaceutical companies with a focus on business development.
Ludger Spitz
ADVISORY BOARD
Specialist in brand development and communication. Senior Product Manager at Bristol Myers Squibb, Global Brand Manager at Novartis.
Ready to discover TRUE Longevity?
Let’s talk.
Whether you’re interested in early access to our first longevity medicine, exploring a partnership, or discussing investment opportunities, we look forward to hearing from you.
